Crossmark Global Holdings Inc. Sells 66 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Crossmark Global Holdings Inc. trimmed its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 1.3% during the 4th quarter, HoldingsChannel.com reports. The fund owned 4,929 shares of the medical research company’s stock after selling 66 shares during the period. Crossmark Global Holdings Inc.’s holdings in Charles River Laboratories International were worth $910,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the company. Empirical Finance LLC boosted its position in shares of Charles River Laboratories International by 4.2% during the third quarter. Empirical Finance LLC now owns 1,310 shares of the medical research company’s stock valued at $258,000 after purchasing an additional 53 shares in the last quarter. American Trust boosted its holdings in shares of Charles River Laboratories International by 5.9% during the 2nd quarter. American Trust now owns 976 shares of the medical research company’s stock valued at $202,000 after buying an additional 54 shares in the last quarter. OLD National Bancorp IN grew its position in shares of Charles River Laboratories International by 3.1% in the 3rd quarter. OLD National Bancorp IN now owns 1,988 shares of the medical research company’s stock worth $392,000 after buying an additional 59 shares during the period. Fiduciary Financial Group LLC increased its stake in shares of Charles River Laboratories International by 3.9% in the 4th quarter. Fiduciary Financial Group LLC now owns 1,665 shares of the medical research company’s stock worth $310,000 after acquiring an additional 63 shares in the last quarter. Finally, Pinnacle Bancorp Inc. lifted its position in Charles River Laboratories International by 52.0% during the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 65 shares during the period. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Wall Street Analysts Forecast Growth

CRL has been the subject of several recent research reports. Redburn Atlantic assumed coverage on shares of Charles River Laboratories International in a report on Monday, October 14th. They set a “sell” rating and a $151.00 target price for the company. Evercore ISI boosted their target price on Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a report on Thursday, November 7th. UBS Group restated a “neutral” rating and set a $185.00 price target (down from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. William Blair lowered Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research report on Wednesday. Finally, TD Cowen increased their price objective on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a research report on Monday, November 11th. Three research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $204.38.

Insiders Place Their Bets

In related news, Director Richard F. Wallman sold 6,621 shares of the business’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the sale, the director now directly owns 12,386 shares in the company, valued at approximately $2,676,862.32. The trade was a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 1.30% of the company’s stock.

Charles River Laboratories International Stock Performance

NYSE CRL opened at $164.88 on Friday. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. Charles River Laboratories International, Inc. has a twelve month low of $160.85 and a twelve month high of $275.00. The business has a 50-day moving average price of $186.75 and a 200-day moving average price of $197.24. The firm has a market cap of $8.43 billion, a price-to-earnings ratio of 20.64, a price-to-earnings-growth ratio of 5.94 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.43 by $0.16. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $975.99 million. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The firm’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same period in the prior year, the company posted $2.72 EPS. As a group, equities research analysts predict that Charles River Laboratories International, Inc. will post 10.18 EPS for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).